Revolution Medicines reports strong launch for pancreatic cancer drug
New pancreatic cancer drug Rasonque brings in nearly $198 million in its first five weeks on the market.
Revolution Medicines (Photo via STAT)
Revolution Medicines announced on Nov. 4 that its new pancreatic cancer treatment, Rasonque, generated $197.6 million in net product revenue during the third quarter of 2026. The financial results cover approximately five weeks of commercial availability following the drug's launch in late August.
The company reported that more than 5,000 unique patients in the United States received the medication through Sept. 30, 2026. Rasonque, also known as daraxonrasib, is a once-daily oral tablet and the first targeted cancer medicine approved from the class of RAS(ON) multi-selective and mutant-selective inhibitors.
The FDA approved Rasonque on Aug. 26, 2026, for adult patients with metastatic pancreatic adenocarcinoma who have undergone at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Approval was based on the Phase 3 RASolute 302 trial, which showed a statistically significant overall survival benefit compared to standard chemotherapy.
Dr. Zev A. Wainberg, a lead investigator for the RASolute 302 trial, noted that the survival benefit was consistent across all evaluated tumor RAS profiles. Dr. Mark A. Goldsmith, CEO and chairman of Revolution Medicines, described the launch as a monumental step for eligible patients.
Looking ahead, the company is preparing for a potential launch in the European Union following a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in October 2026. Revolution Medicines is also currently advancing several Phase 3 clinical trials, including studies focused on first-line metastatic pancreatic cancer.